Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX-100 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PRX-100 | EXPERIMENTAL | PRX-100 ophthalmic solution |
| Placebo | PLACEBO_COMPARATOR | saline solution |
| Name | Type | Description |
|---|---|---|
| PRX-100 | DRUG | ophthalmic solution |
| Placebo | DRUG | saline ophthalmic solution |
Inclusion Criteria: 1. be 45-59 years of age of either sex and any race or ethnicity; 2. be able and willing to provide written informed consent and sign HIPAA form prior to any study procedure being performed; 3. be able and willing to follow all instructions and attend all study visits; 4. have a...
PRX-100 is an investigational small molecule being developed for the treatment of presbyopia, an age-related condition that affects the eye's ability to focus on close objects. It is intended for use in patients with early to moderate presbyopia. The drug is currently in clinical development and has not been approved by regulatory authorities.
PRX-100 is being developed by LENZ Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol LENZ. LENZ Therapeutics is responsible for the clinical development and potential commercialization of PRX-100 for the treatment of presbyopia.
PRX-100 is in Phase 2 clinical development. A Phase 2 clinical trial evaluating the efficacy and safety of PRX-100 in the treatment of early to moderate presbyopia has been completed. The drug is investigational and has not been approved by the FDA or other regulatory agencies.
PRX-100 has been studied in one completed Phase 2 clinical trial with the identifier NCT02554396. This trial was a randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of PRX-100 in the treatment of early to moderate presbyopia. The trial enrolled 20 participants in the United States.
PRX-100 is a small molecule designed to treat presbyopia, a condition that impairs near vision. The specific molecular target of PRX-100 has not been disclosed. The drug is being developed to address the visual symptoms of presbyopia, which typically worsen with age.